Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
38.20
-2.13 (-5.28%)
Mar 31, 2025, 10:52 AM EDT - Market open
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Monopar Therapeutics stock have an average target of 49.6, with a low estimate of 10 and a high estimate of 76. The average target predicts an increase of 29.84% from the current stock price of 38.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $76 | Buy | Initiates | $76 | +98.95% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $40 | Strong Buy | Maintains | $22 → $40 | +4.71% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $72 | Buy | Initiates | $72 | +88.48% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $22 | Strong Buy | Maintains | $6 → $22 | -42.41% | Nov 11, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +30.89% | Oct 11, 2024 |
Financial Forecast
Revenue This Year
80.22M
from 59.84M
Increased by 34.06%
Revenue Next Year
n/a
from 80.22M
EPS This Year
-1.81
from -3.04
EPS Next Year
-2.47
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 29.6M | |||
| Avg | n/a | n/a | 13.3M | |||
| Low | n/a | n/a | 3.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.70 | -1.55 | 0.74 | |||
| Avg | -1.81 | -2.47 | -0.24 | |||
| Low | -1.98 | -3.99 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.